KR19990014875A - 주효세포 조절을 위한 유전자 요법 - Google Patents

주효세포 조절을 위한 유전자 요법 Download PDF

Info

Publication number
KR19990014875A
KR19990014875A KR1019970708220A KR19970708220A KR19990014875A KR 19990014875 A KR19990014875 A KR 19990014875A KR 1019970708220 A KR1019970708220 A KR 1019970708220A KR 19970708220 A KR19970708220 A KR 19970708220A KR 19990014875 A KR19990014875 A KR 19990014875A
Authority
KR
South Korea
Prior art keywords
nucleic acid
acid molecule
cancer
group
pcr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1019970708220A
Other languages
English (en)
Korean (ko)
Inventor
다우스티브더블유
엘므슬리로빈이
포터테런스에이
Original Assignee
크래포 제임스 디
내셔널주이쉬센터포이뮤날러지앤드레스프러토리메디슨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/446,918 external-priority patent/US5705151A/en
Application filed by 크래포 제임스 디, 내셔널주이쉬센터포이뮤날러지앤드레스프러토리메디슨 filed Critical 크래포 제임스 디
Publication of KR19990014875A publication Critical patent/KR19990014875A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1019970708220A 1995-05-18 1996-05-20 주효세포 조절을 위한 유전자 요법 Withdrawn KR19990014875A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/446,918 US5705151A (en) 1995-05-18 1995-05-18 Gene therapy for T cell regulation
US8/446,918 1995-05-18
US8/580,806 1995-12-29
US08/580,806 US5935568A (en) 1995-05-18 1995-12-29 Gene therapy for effector cell regulation

Publications (1)

Publication Number Publication Date
KR19990014875A true KR19990014875A (ko) 1999-02-25

Family

ID=27034800

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970708220A Withdrawn KR19990014875A (ko) 1995-05-18 1996-05-20 주효세포 조절을 위한 유전자 요법

Country Status (8)

Country Link
US (1) US5935568A (cg-RX-API-DMAC10.html)
EP (1) EP0850071A4 (cg-RX-API-DMAC10.html)
JP (1) JPH11508762A (cg-RX-API-DMAC10.html)
KR (1) KR19990014875A (cg-RX-API-DMAC10.html)
AU (1) AU704012B2 (cg-RX-API-DMAC10.html)
CA (1) CA2221305A1 (cg-RX-API-DMAC10.html)
MX (1) MX9708854A (cg-RX-API-DMAC10.html)
WO (1) WO1996036366A1 (cg-RX-API-DMAC10.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075119A (en) * 1997-04-07 2000-06-13 The Rockefeller University Peptides useful for reducing symptoms of toxic shock syndrome
US6713284B2 (en) 1997-06-25 2004-03-30 The United States Of America As Represented By The Secretary Of The Army Bacterial superantigen vaccines
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
DE69837706T2 (de) * 1997-07-21 2008-01-10 Active Biotech Ab Zytolyse der geeigneten zielzellen mit superantigen konjugate mittels der induktion von t-zell aktivierung
WO1999036433A2 (en) * 1998-01-14 1999-07-22 Morphogenesis, Inc. Materials and methods for treating oncological disease
US7348015B2 (en) 1998-01-14 2008-03-25 Morphogenesis, Inc. Antigen modified cancer cell vaccines for cancer therapy
US7795020B2 (en) 1998-01-14 2010-09-14 Morphogenesis, Inc. Tumor cell vaccines
CA2318493A1 (en) * 1998-01-16 1999-07-22 The Johns Hopkins University Oral delivery of nucleic acid vaccines by particulate complexes
WO1999043839A1 (en) * 1998-02-27 1999-09-02 The Trustees Of The University Of Pennsylvania Vaccines, immunotherapeutics and methods for using the same
CA2325818C (en) * 1998-04-20 2008-09-02 Torrey Pines Institute For Molecular Studies Topical immunostimulation to induce langerhans cell migration
ATE315653T1 (de) * 1998-04-22 2006-02-15 Chiron Corp Erhöhung der immunantworten bei genetischer immunisierung durch verwendung eines chemokins
US6919318B1 (en) 1998-04-22 2005-07-19 Chiron Corporation Enhancing immune responses to genetic immunization by using a chemokine
US6086898A (en) * 1998-06-23 2000-07-11 The Board Of Trustees Of The Leland Stanford Junior University Method of converting a Th2-type allergic immune response into a Th1-type immune response
US20040247662A1 (en) * 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en) * 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
AU761021B2 (en) * 1998-07-10 2003-05-29 U.S. Medical Research Institute Of Infectious Diseases Department Of The Army Vaccine against staphylococcus intoxication
MXPA01001631A (es) * 1998-08-13 2002-04-08 Walter Reed Army Inst Of Res D Vacunas de superantigenos bacterianos.
EP1127132A1 (en) * 1998-10-07 2001-08-29 The Rockefeller University Peptides useful for reducing symptoms of toxic shock syndrome and septic shock
US6562800B1 (en) * 1998-10-30 2003-05-13 University Of Southern California Use of immunopotentiating sequences for inducing immune response
WO2000073432A2 (en) * 1999-06-01 2000-12-07 Cornell Research Foundation, Inc. Activation of dendritic cells to enhance immunity
US7361329B2 (en) * 2000-04-21 2008-04-22 Chemocentryx, Inc. Compositions for inducing an immune response
EP1421539B1 (en) 2001-06-14 2009-10-28 The Scripps Research Institute Stabilized factor viii with engineered disulfide bonds
SE0102327D0 (sv) 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
WO2003035106A1 (en) * 2001-10-24 2003-05-01 Chemocentryx Methods and compositions for inducing an immune response by co-administering a chemokine with an antigen
AU2003291402A1 (en) * 2002-11-07 2004-06-03 Beth Israel Deaconess Medical Center MIP-1Alpha AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE
JP4571586B2 (ja) 2003-09-05 2010-10-27 一般財団法人化学及血清療法研究所 プロテアーゼ耐性seb改変体およびそれを含むワクチン
CA2863532A1 (en) * 2012-02-08 2013-08-15 Premune Ab Prevention of inflammatory disorders in domestic non-human mammals

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145676A (en) * 1981-09-08 1992-09-08 The Rockefeller University Method and agents for promoting wound healing
US4994369A (en) * 1987-12-15 1991-02-19 The Board Of Trustees Of The Leland Stanford Jr. Univ. T-cell activation related gene
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
CA2042016C (en) * 1989-09-19 2004-04-06 Jean Content Recombinant polypeptides and peptides, nucleic acids coding for the same and use of these polypeptides and peptides in the diagnostic of tuberculosis
SE8903100D0 (sv) * 1989-09-20 1989-09-20 Pharmacia Ab New pharmaceutical agent
ATE304371T1 (de) * 1990-01-17 2005-09-15 David S Terman Verwendung von staphylococcus enterotoxin homologe für krebs-therapie
WO1993024136A1 (en) * 1991-01-17 1993-12-09 Terman David S Tumor killing effects of enterotoxins, superantigens, and related compounds
EP0499003A1 (en) * 1991-02-14 1992-08-19 N.V. Innogenetics S.A. Polypeptides and peptides, particularly recombinant polypeptides and peptides, nucleic acids coding for the same and use of these polypeptides and peptides in the diagnosis of tuberculosis
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
WO1994004196A1 (en) * 1992-08-14 1994-03-03 Imperial Cancer Research Technology Limited Tumour therapy
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
WO1995000178A1 (en) * 1993-06-25 1995-01-05 Board Of Regents, The University Of Texas System Pore-forming and superantigen encoding toxin cassettes for gene therapy

Also Published As

Publication number Publication date
AU704012B2 (en) 1999-04-01
US5935568A (en) 1999-08-10
WO1996036366A1 (en) 1996-11-21
JPH11508762A (ja) 1999-08-03
MX9708854A (es) 1998-08-30
AU5801696A (en) 1996-11-29
CA2221305A1 (en) 1996-11-21
EP0850071A4 (en) 2005-05-25
EP0850071A1 (en) 1998-07-01

Similar Documents

Publication Publication Date Title
AU704012B2 (en) Gene therapy for effector cell regulation
Parney et al. Glioma immunology and immunotherapy
US5705151A (en) Gene therapy for T cell regulation
Maes et al. Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model
Rakhmilevich et al. Gene gun-mediated IL-12 gene therapy induces antitumor effects in the absence of toxicity: a direct comparison with systemic IL-12 protein therapy
WO1996036366A9 (en) Gene therapy for effector cell regulation
Groux et al. A transgenic model to analyze the immunoregulatory role of IL-10 secreted by antigen-presenting cells
Hung et al. The central role of CD4+ T cells in the antitumor immune response
Rotte et al. Immunotherapy of melanoma: present options and future promises
US5750102A (en) Double transfectants of the MHC genes as cellular vaccines for immuno prevention of tumor metastasis
Giezeman-Smits et al. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity
Graf et al. IL-6 secretion by a rat T9 glioma clone induces a neutrophil-dependent antitumor response with resultant cellular, antiglioma immunity
Ehtesham et al. Recent progress in immunotherapy for malignant glioma: treatment strategies and results from clinical trials
JP2975117B2 (ja) 腫瘍疾患の治療のための生ワクチン
Hara et al. Rejection of mouse melanoma elicited by local secretion of interleukin‐2: Implicating macrophages without T cells or natural killer cells in tumor rejection
Podhajcer et al. Cytokine gene transfer for cancer therapy
JP2007523093A (ja) 非CpG核酸を使用した全身性免疫活性化法
Lichtor et al. Cytokine immuno-gene therapy for treatment of brain tumors
Hsieh et al. IL-6-encoding tumor antigen generates potent cancer immunotherapy through antigen processing and anti-apoptotic pathways
Pizzoferrato et al. Enhanced immunogenicity of B cell lymphoma genetically engineered to express both B7-1 and interleukin-12
Krejci et al. Immunotherapy for urological malignancies
Zhu et al. The treatment and prevention of mouse melanoma with an oral DNA vaccine carried by attenuated Salmonella typhimurium
Li et al. Potent Systemic Antitumor Immunity Induced by Vaccination with Chemotactic-Prostate Tumor Associated Antigen Gene-Modified Tumor Cell and Blockade of B7-H1: li et al.
Weiss et al. The efficacy of an IL-1α Vaccine depends on IL-1RI availability and concomitant myeloid-derived suppressor cell reduction
JP2001010961A (ja) 腫瘍ワクチン

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19971117

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid